Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Gains from Sales and Divestitures (2016 - 2020)

Myriad Genetics (MYGN) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $900000.0 as the latest value for Q2 2020.

  • On a quarterly basis, Gains from Sales and Divestitures rose 12.5% to $900000.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $900000.0, a 12.5% increase, with the full-year FY2020 number at $900000.0, up 12.5% from a year prior.
  • Gains from Sales and Divestitures was $900000.0 for Q2 2020 at Myriad Genetics, roughly flat from $900000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $900000.0 in Q4 2019 to a low of $400000.0 in Q1 2016.
  • A 5-year average of $650000.0 and a median of $700000.0 in 2017 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 1951.28% in 2016, then changed 0.0% in 2017.
  • Myriad Genetics' Gains from Sales and Divestitures stood at $400000.0 in 2016, then skyrocketed by 75.0% to $700000.0 in 2017, then increased by 14.29% to $800000.0 in 2018, then increased by 12.5% to $900000.0 in 2019, then changed by 0.0% to $900000.0 in 2020.
  • Per Business Quant, the three most recent readings for MYGN's Gains from Sales and Divestitures are $900000.0 (Q2 2020), $900000.0 (Q1 2020), and $900000.0 (Q4 2019).